Posted by Michael Wonder on 12 Mar 2025
Natalizumab for the treatment of patients with highly active relapsing–remitting multiple sclerosis after disease-modifying therapy
12 March 2025 - The Department of Health and Social Care has asked NICE to produce guidance on the use of natalizumab in the NHS in England.
For the time being, natalizumab (originator and biosimilar) is not recommended for the treatment of adults with relapsing–remitting multiple sclerosis that is highly active despite a full and adequate course of at least one disease-modifying therapy.
